prostate cancer

Spacer system maintains QoL at 3 years post RTPhase III study results suggest that a hydrogel spacer developed to separate the rectum and prostate during radiotherapy for prostate cancer works to maintain bowel and urinary quality of life and reduces late rectal toxicity by 78% at 3 years post radiotherapy.
Biomarkers predict metastasis, biochemical recurrenceClinicians may soon be able to improve the risk stratification of men with prostate cancer with the help of a genomic classifier or a biopsy-based reverse transcription polymerase chain reaction assay, according to the results of two studies presented at the Genitourinary Cancers Symposium in Orlando, FL.
Novel assay may help identify prostate Bx candidatesA simple blood test that measures PSA structure rather than concentration may be more accurate than PSA in identifying men who need a prostate biopsy, according to the results of a study presented at the Genitourinary Cancers Symposium in Orlando, FL.
Role of molecular biomarkers in localized prostate cancer
Hypofractionated IMRT outcomes comparable to standard regimen“We showed that we can safely compress radiation into a shorter time frame, into fewer treatments, at higher dose per fraction, with similar clinical outcomes and similar toxicity profiles,” said researcher Michael Wang, MD.
AUA 2017: A small-town plumber’s 10 can’t-miss sessionsIn preparation for the AUA annual meeting in May, urologist Henry Rosevear, MD, shares the 10 sessions he’s looking forward to the most.
Researchers validate prognostic model for mCRPCResearchers have developed and validated a clinically useful prognostic model for men with metastatic castration-resistant prostate cancer, which can be used in the front-line setting.
Day of RP affects complication rates, length of stayRadical prostatectomy performed on a Friday is associated with a higher complication rate and extended hospital stay compared with the same surgery performed on other days of the week.
Genetic predictors could improve PSA accuracyA recent study has found that genetic predictors of normal PSA levels in healthy men could be used to improve the accuracy of PSA-based prostate cancer screening.
Urology FDA approvals of 2016Urology-related FDA approvals from 2016 encompassed drugs and devices for prostate cancer, renal cell carcinoma, bladder cancer, stone disease, and more.